Literature DB >> 30371826

Latent Structure of the Cigarette Purchase Task Among Treatment-Seeking Smokers With Depression and Its Predictive Validity on Smoking Abstinence.

Alba González-Roz1, Roberto Secades-Villa1, Sara Weidberg1, Ángel García-Pérez1, Derek D Reed2.   

Abstract

INTRODUCTION: Research has recently shown that nicotine reinforcement is better characterized by a bifactorial latent structure: persistence (insensitivity to cigarette pricing) and amplitude (consumption at inexpensive prices). No study to date has examined its value as a predictor of abstinence. This study aimed to provide new evidence on the latent structure of the cigarette purchase task (CPT) in smokers with depressive symptoms and to examine whether the latent structure performs better as a predictor of continuous abstinence than do the individual indices.
METHODS: Participants (n = 205 smokers; 72% female: Beck Depression Inventory, Second Edition, M = 24.68, SD = 10.45) were randomized to two smoking cessation treatments for quitting smoking: cognitive behavioral treatment (CBT) or CBT + contingency management (CM). A principal-components analysis was conducted to examine the latent structure of the CPT and a set of regression models were performed to assess its predictive validity.
RESULTS: The principal-components analysis revealed a bifactorial solution, which was interpreted as persistence (breakpoint, Omax, Pmax, and elasticity) and psychological inertia (intensity and elasticity of demand). Evidence on the convergent validity was obtained through significant associations between the two latent factors and smoking variables (all r values ≥.17). Psychological inertia was negatively related to the number of days of continuous abstinence at the end of treatment regardless of the treatment condition [R2 = .038; F(2, 202) = 4.989, p = .008].
CONCLUSIONS: Psychological inertia informs on which patients benefit less from smoking cessation treatments incorporating CM and CBT. Treatment components that affect individuals' excessive valuation of cigarettes might improve cessation outcomes. IMPLICATIONS: This is the first attempt to examine the latent structure of the CPT in depressed smokers and to yield evidence on its predictive validity. A specific bifactorial solution exists for this population: persistence (breakpoint, Omax, Pmax, and elasticity) and psychological inertia (intensity and elasticity). Isolating demand indices and factors provides a high-resolution characterization of nicotine reinforcement for depressed smokers in that it informs on treatment response. Compared to the individual CPT indices, psychological inertia more effectively predicts which patients benefit most from either CM or CBT. Treatment components that affect individuals' excessive valuation of cigarettes (eg, episodic future thinking) should be integrated into smoking cessation treatments.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 30371826     DOI: 10.1093/ntr/nty236

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  8 in total

1.  Validation of an E-cigarette Purchase Task in Advanced Generation Device Users.

Authors:  Rachel N Cassidy; Victoria Long; Jennifer W Tidey; Suzanne M Colby
Journal:  Nicotine Tob Res       Date:  2020-10-08       Impact factor: 4.244

2.  Using the Cigarette Purchase Task to examine the relative reinforcing value of cigarettes among mothers with versus without opioid dependence.

Authors:  Tyler D Nighbor; Sulamunn R M Coleman; Janice Y Bunn; Michael J DeSarno; Adam L Morehead; Katherine J Tang; Diana R Keith; Shirley T Plucinski; Allison N Kurti; Ivori Zvorsky; Stephen T Higgins
Journal:  Exp Clin Psychopharmacol       Date:  2020-02-27       Impact factor: 3.157

3.  Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations.

Authors:  Stephen T Higgins; Michael DeSarno; Danielle R Davis; Tyler Nighbor; Joanna M Streck; Shana Adise; Roxanne Harfmann; Riley Nesheim-Case; Catherine Markesich; Derek Reed; Rachel F Tyndale; Diann E Gaalema; Sarah H Heil; Stacey C Sigmon; Jennifer W Tidey; Andrea C Villanti; Dustin Lee; John R Hughes; Janice Y Bunn
Journal:  Prev Med       Date:  2020-07-03       Impact factor: 4.018

4.  Sensitivity of hypothetical purchase task indices when studying substance use: A systematic literature review.

Authors:  Ivori Zvorsky; Tyler D Nighbor; Allison N Kurti; Michael DeSarno; Gideon Naudé; Derek D Reed; Stephen T Higgins
Journal:  Prev Med       Date:  2019-08-07       Impact factor: 4.018

5.  Using crowdsourcing to study the differential effects of cross-drug withdrawal for cigarettes and opioids in a behavioral economic demand framework.

Authors:  Mark J Rzeszutek; Cassandra D Gipson-Reichardt; Brent A Kaplan; Mikhail N Koffarnus
Journal:  Exp Clin Psychopharmacol       Date:  2022-02-24       Impact factor: 3.492

6.  No evidence of the clinical utility of single-item breakpoint to inform on tobacco demand in persons with substance use disorders.

Authors:  Alba González-Roz; Roberto Secades-Villa; Gema Aonso-Diego; Sara Weidberg; José R Fernández-Hermida
Journal:  Psychopharmacology (Berl)       Date:  2021-05-24       Impact factor: 4.530

7.  E-Cigarette Demand: Impact of Commodity Definitions and Test-Retest Reliability.

Authors:  Justin C Strickland; Olga A Vsevolozhskaya; William W Stoops
Journal:  Nicotine Tob Res       Date:  2021-02-16       Impact factor: 4.244

8.  Behavioral Economic Assessment of Alcohol and Cigarette Demand in Smokers With Alcohol Use Disorder.

Authors:  Yong Cui; Paulina Linares Abrego; Jin Ho Yoon; Maher Karam-Hage; Paul M Cinciripini; Nassima Ait-Daoud Tiouririne; Robert M Anthenelli; Jason D Robinson
Journal:  Front Psychiatry       Date:  2021-06-23       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.